search
Back to results

Brief-intensive CBT Versus Once-weekly CBT in Anxiety-related Disorders (KOMMA)

Primary Purpose

Anxiety Disorders, Obsessive-Compulsive Disorder, Posttraumatic Stress Disorder

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Cognitive behavioral therapy (CBT)
Sponsored by
Free University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anxiety Disorders focused on measuring agoraphobia, social anxiety disorder, generalized anxiety disorder, panic disorder, trauma, health anxiety, obsessive compulsive disorder, CBT

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age 18 years or older; Reaching out for mental health care for one of the following disorders: panic disorder, agoraphobia, generalised anxiety disorder, social anxiety disorder, posttraumatic stress disorder, obsessive-compulsive disorder, health anxiety disorder. Exclusion Criteria: Is in need of emergency mental health care Has insufficient language skills in Dutch Has evident cognitive limitations Has had changes in the use of medication during the last 3 months.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Brief-Intensive CBT

    weekly CBT

    Arm Description

    16 sessions in 2 weeks + 4 follow up sessions. The CBT consists of 16 sessions exposure therapy, spread over 4 half-days in 2 weeks, + 4 sessions within 3 months.

    20 weekly CBT sessions within 5 to 6 months. The CBT consists of exposure therapy.

    Outcomes

    Primary Outcome Measures

    Area Under the health and disability Curve at 6 months
    The 'area under the curve' for health and disability is based on the 36-item self-report World Health Organisation Disability Assessment Schedule (WHODAS 2.0). The WHODAS 2.0 captures the level of functioning in six domains of life: Cognition, Mobility, Self-care, Getting along, Life activities, Participation. Possible total scores of the items across all domains range 0 - 100. Lower scores indicate less disability.

    Secondary Outcome Measures

    Area Under the health and disability Curve at 12 months
    The 'area under the curve' for health and disability is based on the 36-item self-report World Health Organisation Disability Assessment Schedule (WHODAS 2.0). The WHODAS 2.0 captures the level of functioning in six domains of life: Cognition, Mobility, Self-care, Getting along, Life activities, Participation. Possible total scores of the items across all domains range 0 - 100. Lower scores indicate less disability.
    Change from baseline in severity of anxiety symptoms at post-treatment
    Severity of anxiety-related disorder, measured with the following disorder-specific severity questionnaires: the 24-item Liebowitz Social Anxiety Scale self-report version, the 7-item Panic Disorder Severity Scale self-report version, the 15-item Fear Questionnaire, the 16-item Penn State Worry Questionnaire, the 10-item Yale-Brown Obsessive Compulsive Scale self-report version, the 20-item PTSD checklist for the DSM-5, or the 14-item Whitely Index. Higher scores indicate higher symptom severity. Z-scores will be calculated from individual scores for group-level analyses.
    Change from baseline in severity of anxiety symptoms at 3 months
    Severity of anxiety-related disorder, measured with the following disorder-specific severity questionnaires: the 24-item Liebowitz Social Anxiety Scale self-report version, the 7-item Panic Disorder Severity Scale self-report version, the 15-item Fear Questionnaire, the 16-item Penn State Worry Questionnaire, the 10-item Yale-Brown Obsessive Compulsive Scale self-report version, the 20-item PTSD checklist for the DSM-5, or the 14-item Whitely Index. Higher scores indicate higher symptom severity. Z-scores will be calculated from individual scores for group-level analyses.
    Change from baseline in severity of anxiety symptoms at 12 months
    Severity of anxiety-related disorder, measured with the following disorder-specific severity questionnaires: the 24-item Liebowitz Social Anxiety Scale self-report version, the 7-item Panic Disorder Severity Scale self-report version, the 15-item Fear Questionnaire, the 16-item Penn State Worry Questionnaire, the 10-item Yale-Brown Obsessive Compulsive Scale self-report version, the 20-item PTSD checklist for the DSM-5, or the 14-item Whitely Index. Higher scores indicate higher symptom severity. Z-scores will be calculated from individual scores for group-level analyses.
    Change from baseline in severity of depressive symptoms at post-treatment
    Severity of depressive symptoms are measured with the 30-item Inventory for Depressive Symptomatology self-report questionnaire. Higher scores indicate higher symptom severity.
    Change from baseline in severity of depressive symptoms at 3 months
    Severity of depressive symptoms are measured with the 30-item Inventory for Depressive Symptomatology self-report questionnaire. Higher scores indicate higher symptom severity.
    Change from baseline in severity of depressive symptoms at 12 months
    Severity of depressive symptoms are measured with the 30-item Inventory for Depressive Symptomatology self-report questionnaire. Higher scores indicate higher symptom severity.
    Remission rates from anxiety-related disorder at post-treatment
    Remission of diagnoses of anxiety-related disorders is assessed using the Mini International Neuropsychiatric Interview - Simplified for DSM-5, Dutch version 1.1 (Overbeek & Schruers, 2019).
    Remission rates from anxiety-related disorder at 12 months
    Remission of diagnoses of anxiety-related disorders is assessed using the Mini International Neuropsychiatric Interview - Simplified for DSM-5, Dutch version 1.1 (Overbeek & Schruers, 2019).
    New-onset anxiety-related or depressive disorder post-treatment
    The new onset of anxiety-related or depressive disorder between baseline and post-treatment is assessed using the Mini International Neuropsychiatric Interview - Simplified for DSM-5, Dutch version 1.1 (Overbeek & Schruers, 2019)
    New-onset anxiety-related or depressive disorder at 12 months
    The new onset of anxiety-related or depressive disorder between baseline and post-treatment is assessed using the Mini International Neuropsychiatric Interview - Simplified for DSM-5, Dutch version 1.1 (Overbeek & Schruers, 2019)
    Productivity costs over 12 months
    Productivity losses are assessed using the iMTA Productivity Cost Questionnaire (iPCQ). The iPCQ is a 12-item self-report questionnaire including three modules measuring productivity losses of paid work due to 1) absenteeism and 2) presenteeism and productivity losses related to 3) unpaid work in the past 3 months.
    Medical costs over 12 months
    Medical costs from a mental health care perspective are assessed using the iMTA Medical Cost Questionnaire (iMCQ). The iMCQ is a 23-item self-report questionnaire, which apart from some general questions include questions on medical consumption from different healthcare providers in the past 3 months.
    Change from baseline in health-related quality of life over 12 months
    Quality of life is measured using the EQ-5D-5L. The EQ-5D-5L scores (reflecting the level of perceived problems on the dimensions of mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are used to calculate utilities using the Dutch tariff. Quality Adjusted Life Years are calculated using linear interpolation between time points. Higher QALY scores indicate more improvement in quality of life.
    Drop-out rates at post-treatment
    Percentage of patiënts who missed more than 25% of CBT sessions.
    Patient satisfaction at post-treatment
    The 3-item CSQ-3 include the CSQScales® items most salient to the measurement of The three items of the CSQ are the main items for measuring overall satisfaction of health and human services. Each item on the CSQ-3 is scored from 1 (low satisfaction) to 4 (high satisfaction), possible total scores ranging 3-12.

    Full Information

    First Posted
    June 16, 2023
    Last Updated
    July 4, 2023
    Sponsor
    Free University Medical Center
    Collaborators
    Netherlands Brain Foundation
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05942391
    Brief Title
    Brief-intensive CBT Versus Once-weekly CBT in Anxiety-related Disorders
    Acronym
    KOMMA
    Official Title
    Fast Recovery From Anxiety-related Disorders: Brief-intensive CBT Versus Once-weekly CBT
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    December 1, 2023 (Anticipated)
    Primary Completion Date
    March 31, 2026 (Anticipated)
    Study Completion Date
    September 30, 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Free University Medical Center
    Collaborators
    Netherlands Brain Foundation

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The goal of this clinical trial is to compare brief-intensive cognitive-behaviour therapy (CBT) with regular weekly CBT in people with anxiety-related disorders. The main question to answer is: will brief-intensive CBT improve functioning (work, family, social) more and faster than does regular weekly CBT? Participants will be asked to follow CBT treatment (20 sessions of 45 minutes in both conditions), and participate in 7 measurements with a total duration of 5 hours over 1 year. Researchers will compare: Brief-intensive CBT: 16 sessions in 2 weeks + 4 follow-up sessions within 3 months Regular CBT with 20 weekly sessions in 6 months
    Detailed Description
    Rationale: Anxiety-related disorders (i.e., obsessive compulsive, health anxiety and trauma disorders) affect about 10% of the adults. Though clinically heterogeneous, transdiagnostic aspects are expected disasters, anxiety and avoidance. Profound impairments include work and family functioning. Many enter a vicious circle with comorbidity and further decline in quality of life. Hence, the impact on functioning is tremendous, with anxiety-related disorders rating highest on disability rankings in the age 15-64 years. Cognitive behavioral therapy (CBT) is the preferred and often only psychotherapy for these disorders. Because guidelines are based on weekly sessions, recovery takes half a year at least. Based on initial research findings, we expect faster recovery by providing CBT in a brief-intensive format (BI-CBT), with clear benefts for patients, families and society. Some institutions already provide BI-CBT. However, evidence to justify this or to further implement BI-CBT is insufficient. Study design: a parallel-group randomised controlled multicenter intervention study. Study population: Adults aged 18-65 yr old with an anxiety-related disorder (panic, agrophobia, social anxiety, generalised anxiety obsessions/compulsions, health anxiety and post-traumatic stress) Intervention (if applicable): One group receives BI-CBT (16 sessions in 2 weeks + 4 follow up sessions) and the other group receives 20 weekly CBT sessions. Treatment in both conditions can be personalised by a focus on work or family functioning. Main study parameters/endpoints: The main study parameter is the 'area under the curve' for 6-month health and disability. Also, 1 year efficacy (both on functioning and symptom-level), cost-effectiveness, and feasibility will be assessed. Potential predictors of treatment preference, efficacy and drop-out will be explored. All patients are expected to follow CBT (20 sessions of 45min) and participate in 7 measurements over 1 year. The general measurements are online questionnaires and interviews by telephone, asking about someones functioning, quality of life and symptoms of anxiety or depression, how one copes with these and what one expects of the therapy. The acronym KOMMA is based on the Dutch translation of 'to put a quick end to anxiety': Korte Metten Met Angst.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Anxiety Disorders, Obsessive-Compulsive Disorder, Posttraumatic Stress Disorder, Hypochondriasis
    Keywords
    agoraphobia, social anxiety disorder, generalized anxiety disorder, panic disorder, trauma, health anxiety, obsessive compulsive disorder, CBT

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    a parallel-group randomised controlled intervention study
    Masking
    Outcomes Assessor
    Allocation
    Randomized
    Enrollment
    120 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Brief-Intensive CBT
    Arm Type
    Experimental
    Arm Description
    16 sessions in 2 weeks + 4 follow up sessions. The CBT consists of 16 sessions exposure therapy, spread over 4 half-days in 2 weeks, + 4 sessions within 3 months.
    Arm Title
    weekly CBT
    Arm Type
    Active Comparator
    Arm Description
    20 weekly CBT sessions within 5 to 6 months. The CBT consists of exposure therapy.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Cognitive behavioral therapy (CBT)
    Other Intervention Name(s)
    exposure therapy
    Intervention Description
    The intervention is brief-intensive, guided exposure therapy and consists of 16 sessions exposure therapy, spread over 4 half-days in 2 weeks plus 4 follow-up sessions within 3 months.
    Primary Outcome Measure Information:
    Title
    Area Under the health and disability Curve at 6 months
    Description
    The 'area under the curve' for health and disability is based on the 36-item self-report World Health Organisation Disability Assessment Schedule (WHODAS 2.0). The WHODAS 2.0 captures the level of functioning in six domains of life: Cognition, Mobility, Self-care, Getting along, Life activities, Participation. Possible total scores of the items across all domains range 0 - 100. Lower scores indicate less disability.
    Time Frame
    baseline, 2 weeks, 4 weeks, 2 months, 3 months, 6 months
    Secondary Outcome Measure Information:
    Title
    Area Under the health and disability Curve at 12 months
    Description
    The 'area under the curve' for health and disability is based on the 36-item self-report World Health Organisation Disability Assessment Schedule (WHODAS 2.0). The WHODAS 2.0 captures the level of functioning in six domains of life: Cognition, Mobility, Self-care, Getting along, Life activities, Participation. Possible total scores of the items across all domains range 0 - 100. Lower scores indicate less disability.
    Time Frame
    baseline, 2 weeks, 4 weeks, 2 months, 3 months, 6 months, 12 months
    Title
    Change from baseline in severity of anxiety symptoms at post-treatment
    Description
    Severity of anxiety-related disorder, measured with the following disorder-specific severity questionnaires: the 24-item Liebowitz Social Anxiety Scale self-report version, the 7-item Panic Disorder Severity Scale self-report version, the 15-item Fear Questionnaire, the 16-item Penn State Worry Questionnaire, the 10-item Yale-Brown Obsessive Compulsive Scale self-report version, the 20-item PTSD checklist for the DSM-5, or the 14-item Whitely Index. Higher scores indicate higher symptom severity. Z-scores will be calculated from individual scores for group-level analyses.
    Time Frame
    baseline and 3 or 6 months
    Title
    Change from baseline in severity of anxiety symptoms at 3 months
    Description
    Severity of anxiety-related disorder, measured with the following disorder-specific severity questionnaires: the 24-item Liebowitz Social Anxiety Scale self-report version, the 7-item Panic Disorder Severity Scale self-report version, the 15-item Fear Questionnaire, the 16-item Penn State Worry Questionnaire, the 10-item Yale-Brown Obsessive Compulsive Scale self-report version, the 20-item PTSD checklist for the DSM-5, or the 14-item Whitely Index. Higher scores indicate higher symptom severity. Z-scores will be calculated from individual scores for group-level analyses.
    Time Frame
    baseline and 3 months
    Title
    Change from baseline in severity of anxiety symptoms at 12 months
    Description
    Severity of anxiety-related disorder, measured with the following disorder-specific severity questionnaires: the 24-item Liebowitz Social Anxiety Scale self-report version, the 7-item Panic Disorder Severity Scale self-report version, the 15-item Fear Questionnaire, the 16-item Penn State Worry Questionnaire, the 10-item Yale-Brown Obsessive Compulsive Scale self-report version, the 20-item PTSD checklist for the DSM-5, or the 14-item Whitely Index. Higher scores indicate higher symptom severity. Z-scores will be calculated from individual scores for group-level analyses.
    Time Frame
    baseline and 12 months
    Title
    Change from baseline in severity of depressive symptoms at post-treatment
    Description
    Severity of depressive symptoms are measured with the 30-item Inventory for Depressive Symptomatology self-report questionnaire. Higher scores indicate higher symptom severity.
    Time Frame
    baseline and 3 or 6 months
    Title
    Change from baseline in severity of depressive symptoms at 3 months
    Description
    Severity of depressive symptoms are measured with the 30-item Inventory for Depressive Symptomatology self-report questionnaire. Higher scores indicate higher symptom severity.
    Time Frame
    baseline and 3 months
    Title
    Change from baseline in severity of depressive symptoms at 12 months
    Description
    Severity of depressive symptoms are measured with the 30-item Inventory for Depressive Symptomatology self-report questionnaire. Higher scores indicate higher symptom severity.
    Time Frame
    baseline and 12 months
    Title
    Remission rates from anxiety-related disorder at post-treatment
    Description
    Remission of diagnoses of anxiety-related disorders is assessed using the Mini International Neuropsychiatric Interview - Simplified for DSM-5, Dutch version 1.1 (Overbeek & Schruers, 2019).
    Time Frame
    3 or 6 months
    Title
    Remission rates from anxiety-related disorder at 12 months
    Description
    Remission of diagnoses of anxiety-related disorders is assessed using the Mini International Neuropsychiatric Interview - Simplified for DSM-5, Dutch version 1.1 (Overbeek & Schruers, 2019).
    Time Frame
    12 months
    Title
    New-onset anxiety-related or depressive disorder post-treatment
    Description
    The new onset of anxiety-related or depressive disorder between baseline and post-treatment is assessed using the Mini International Neuropsychiatric Interview - Simplified for DSM-5, Dutch version 1.1 (Overbeek & Schruers, 2019)
    Time Frame
    baseline, 3 or 6 months
    Title
    New-onset anxiety-related or depressive disorder at 12 months
    Description
    The new onset of anxiety-related or depressive disorder between baseline and post-treatment is assessed using the Mini International Neuropsychiatric Interview - Simplified for DSM-5, Dutch version 1.1 (Overbeek & Schruers, 2019)
    Time Frame
    12 months
    Title
    Productivity costs over 12 months
    Description
    Productivity losses are assessed using the iMTA Productivity Cost Questionnaire (iPCQ). The iPCQ is a 12-item self-report questionnaire including three modules measuring productivity losses of paid work due to 1) absenteeism and 2) presenteeism and productivity losses related to 3) unpaid work in the past 3 months.
    Time Frame
    3months, 6months, 12 months
    Title
    Medical costs over 12 months
    Description
    Medical costs from a mental health care perspective are assessed using the iMTA Medical Cost Questionnaire (iMCQ). The iMCQ is a 23-item self-report questionnaire, which apart from some general questions include questions on medical consumption from different healthcare providers in the past 3 months.
    Time Frame
    3months, 6months, 12 months
    Title
    Change from baseline in health-related quality of life over 12 months
    Description
    Quality of life is measured using the EQ-5D-5L. The EQ-5D-5L scores (reflecting the level of perceived problems on the dimensions of mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are used to calculate utilities using the Dutch tariff. Quality Adjusted Life Years are calculated using linear interpolation between time points. Higher QALY scores indicate more improvement in quality of life.
    Time Frame
    baseline, 2 weeks, 4 weeks, 2 months, 3 months, 6 months, 12 months
    Title
    Drop-out rates at post-treatment
    Description
    Percentage of patiënts who missed more than 25% of CBT sessions.
    Time Frame
    3 or 6 months
    Title
    Patient satisfaction at post-treatment
    Description
    The 3-item CSQ-3 include the CSQScales® items most salient to the measurement of The three items of the CSQ are the main items for measuring overall satisfaction of health and human services. Each item on the CSQ-3 is scored from 1 (low satisfaction) to 4 (high satisfaction), possible total scores ranging 3-12.
    Time Frame
    3 or 6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age 18 years or older; Reaching out for mental health care for one of the following disorders: panic disorder, agoraphobia, generalised anxiety disorder, social anxiety disorder, posttraumatic stress disorder, obsessive-compulsive disorder, health anxiety disorder. Exclusion Criteria: Is in need of emergency mental health care Has insufficient language skills in Dutch Has evident cognitive limitations Has had changes in the use of medication during the last 3 months.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Adrie Seldenrijk, PhD
    Phone
    0031681173478
    Email
    a.seldenrijk@ggzingeest.nl
    First Name & Middle Initial & Last Name or Official Title & Degree
    Willemijn Scholten, PhD
    Phone
    0031207885000
    Email
    w.scholten@ggzingeest.nl
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Neeltje Batelaan, PhD
    Organizational Affiliation
    Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Brief-intensive CBT Versus Once-weekly CBT in Anxiety-related Disorders

    We'll reach out to this number within 24 hrs